Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Turning Point Therapeutics appoints Paolo Tombesi as CFO » 09:02
06/29/21
06/29
09:02
06/29/21
09:02
TPTX

Turning Point Therapeutics

$76.60 /

-3.6 (-4.49%)

, EPZM

Epizyme

$9.44 /

-0.275 (-2.83%)

Turning Point…

Turning Point Therapeutics (TPTX) named Paolo Tombesi as executive vice president and CFO, effective July 26. Tombesi brings 30 years of global financial and accounting experience to Turning Point from multiple prior financial leadership roles within biotech and pharmaceutical companies, most recently serving as CFO of Epizyme (EPZM).

ShowHide Related Items >><<
TPTX Turning Point Therapeutics
$76.60 /

-3.6 (-4.49%)

EPZM Epizyme
$9.44 /

-0.275 (-2.83%)

TPTX Turning Point Therapeutics
$76.60 /

-3.6 (-4.49%)

05/06/21 Roth Capital
Turning Point 'significantly undervalued' with catalysts ahead, says Roth
04/13/21 Roth Capital
Turning Point combo data show 'expansive pipeline potential,' says Roth Capital
04/06/21 Roth Capital
Turning Point price target raised to $175 from $170 at Roth Capital
03/02/21 Roth Capital
Turning Point has 'many value-driving catalysts' in 2021, says Roth Capital
EPZM Epizyme
$9.44 /

-0.275 (-2.83%)

05/07/21 SVB Leerink
Epizyme upgraded to Outperform from Market Perform at SVB Leerink
04/23/21 Cowen
Epizyme transferred with Outperform at Cowen
03/30/21 Credit Suisse
Epizyme initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Epizyme initiated with an Outperform at Credit Suisse
TPTX Turning Point Therapeutics
$76.60 /

-3.6 (-4.49%)

EPZM Epizyme
$9.44 /

-0.275 (-2.83%)

  • 27
    Oct
EPZM Epizyme
$9.44 /

-0.275 (-2.83%)

TPTX Turning Point Therapeutics
$76.60 /

-3.6 (-4.49%)

Over a month ago
Hot Stocks
Turning Point Therapeutics granted FDA orphan drug designation for TPX-022 » 08:38
06/17/21
06/17
08:38
06/17/21
08:38
TPTX

Turning Point Therapeutics

$77.55 /

-0.47 (-0.60%)

Turning Point…

Turning Point Therapeutics announced that TPX-0022, the company's inhibitor of MET and the associated cancer signaling pathways of SRC and CSF1R, has been granted orphan drug designation by the Food and Drug Administration for the treatment of patients with gastric cancer, including gastroesophageal junction adenocarcinoma. TPX-0022 is a potent inhibitor of the MET tyrosine kinase and has the potential to modulate the tumor microenvironment to augment its therapeutic effect. Initial clinical data presented from the ongoing Phase 1 SHIELD-1 study in October 2020 showed TPX-0022 has been generally well-tolerated and demonstrated clinical activity in patients with MET-amplified gastric cancer.

ShowHide Related Items >><<
TPTX Turning Point Therapeutics
$77.55 /

-0.47 (-0.60%)

TPTX Turning Point Therapeutics
$77.55 /

-0.47 (-0.60%)

05/06/21 Roth Capital
Turning Point 'significantly undervalued' with catalysts ahead, says Roth
04/13/21 Roth Capital
Turning Point combo data show 'expansive pipeline potential,' says Roth Capital
04/06/21 Roth Capital
Turning Point price target raised to $175 from $170 at Roth Capital
03/02/21 Roth Capital
Turning Point has 'many value-driving catalysts' in 2021, says Roth Capital
TPTX Turning Point Therapeutics
$77.55 /

-0.47 (-0.60%)

  • 27
    Oct
TPTX Turning Point Therapeutics
$77.55 /

-0.47 (-0.60%)

Hot Stocks
Zai Lab announces first patient treated in China in Phase 2 TRIDENT-1 study » 07:33
05/28/21
05/28
07:33
05/28/21
07:33
ZLAB

Zai Lab

$168.96 /

+4.42 (+2.69%)

, TPTX

Turning Point Therapeutics

$67.82 /

-0.74 (-1.08%)

Zai Lab (ZLAB) announced…

Zai Lab (ZLAB) announced dosing of the first patient in China in the registrational Phase 2 portion of TRIDENT-1 study of repotrectinib being conducted by its partner Turning Point Therapeutics (TPTX) and Zai Lab in patients with ROS1+ advanced non-small cell lung cancer and NTRK+ advanced solid tumors. Zai Lab has an exclusive license agreement with Turning Point for the development and commercialization of repotrectinib in Greater China. The registrational Phase 2 portion of TRIDENT-1 study is a multi-center trial evaluating repotrectinib for the treatment of patients with ROS1+ advanced NSCLC as well as patients with NTRK+ advanced solid tumors. The primary endpoint of the Phase 2 portion of the trial is overall response rate assessed by Blinded Independent Central Review. Secondary endpoints include duration of response, progression free survival, safety and tolerability. Zai Lab is enrolling patients in Greater China, while Turning Point is enrolling patients in other regions of the world. Turning Point disclosed on May 5 that the FDA recently guided that a type B meeting should be requested to discuss topline BICR results of cohort 1 of the registrational TRIDENT-1 study when responders have been followed for at least six months past onset of response. Turning Point believes it may be in a position to discuss the topline results from patients treated within EXP-1 with the FDA during the first quarter of 2022.

ShowHide Related Items >><<
ZLAB Zai Lab
$168.96 /

+4.42 (+2.69%)

TPTX Turning Point Therapeutics
$67.82 /

-0.74 (-1.08%)

ZLAB Zai Lab
$168.96 /

+4.42 (+2.69%)

04/14/21 SVB Leerink
Zai Lab price target raised to $192 from $183 at SVB Leerink
04/13/21 Goldman Sachs
Zai Lab price target raised to $211.23 after LUNAR trial update at Goldman Sachs
04/13/21 Guggenheim
Zai Lab price target raised to $250 from $165 at Guggenheim
02/08/21 Jefferies
Zai Lab price target raised to $225 upon assumption at Jefferies
TPTX Turning Point Therapeutics
$67.82 /

-0.74 (-1.08%)

05/06/21 Roth Capital
Turning Point 'significantly undervalued' with catalysts ahead, says Roth
04/13/21 Roth Capital
Turning Point combo data show 'expansive pipeline potential,' says Roth Capital
04/06/21 Roth Capital
Turning Point price target raised to $175 from $170 at Roth Capital
03/02/21 Roth Capital
Turning Point has 'many value-driving catalysts' in 2021, says Roth Capital
ZLAB Zai Lab
$168.96 /

+4.42 (+2.69%)

TPTX Turning Point Therapeutics
$67.82 /

-0.74 (-1.08%)

  • 21
    Apr
  • 27
    Oct
ZLAB Zai Lab
$168.96 /

+4.42 (+2.69%)

TPTX Turning Point Therapeutics
$67.82 /

-0.74 (-1.08%)

Hot Stocks
Turning Point Therapeutics appoints Mark Alles as chair of board » 09:02
05/25/21
05/25
09:02
05/25/21
09:02
TPTX

Turning Point Therapeutics

$70.46 /

+0.24 (+0.34%)

Turning Point…

Turning Point Therapeutics announced the appointment of former Celgene chairman and CEO, Mark Alles, to chair its board of directors. Garry Nicholson, who is currently the interim chair, will remain on the board.

ShowHide Related Items >><<
TPTX Turning Point Therapeutics
$70.46 /

+0.24 (+0.34%)

TPTX Turning Point Therapeutics
$70.46 /

+0.24 (+0.34%)

05/06/21 Roth Capital
Turning Point 'significantly undervalued' with catalysts ahead, says Roth
04/13/21 Roth Capital
Turning Point combo data show 'expansive pipeline potential,' says Roth Capital
04/06/21 Roth Capital
Turning Point price target raised to $175 from $170 at Roth Capital
03/02/21 Roth Capital
Turning Point has 'many value-driving catalysts' in 2021, says Roth Capital
TPTX Turning Point Therapeutics
$70.46 /

+0.24 (+0.34%)

  • 27
    Oct
TPTX Turning Point Therapeutics
$70.46 /

+0.24 (+0.34%)

Hot Stocks
Turning Point Therapeutics appoints Kumar Srinivasan as Chief Business Officer » 09:03
05/17/21
05/17
09:03
05/17/21
09:03
TPTX

Turning Point Therapeutics

$69.35 /

+1.05 (+1.54%)

, AZN

AstraZeneca

$55.24 /

+0.19 (+0.35%)

Turning Point…

Turning Point Therapeutics (TPTX) announced the appointment of Kumar Srinivasan as executive vice president and Chief Business Officer, effective June 1. Srinivasan has over 20 years of experience in pharmaceutical and biotechnology companies, most recently as vice president and global head of business development for the BioPharmaceutical business unit of AstraZeneca (AZN). Srinivasan will be responsible for corporate strategy and business development, including collaborations and alliances. During his 9-year tenure at AstraZeneca, Srinivasan was responsible for all in- and out-licensing, business development and alliance management activities within several therapeutic areas on a regional and global scale. In addition, he previously held executive level business development roles at Wyeth; Vivoryon, a publicly traded biotech based in Germany; and Torrey Pines Therapeutics. Earlier in his career, he held scientific roles at biopharmaceutical companies, Sibia Neurosciences and Genta.

ShowHide Related Items >><<
TPTX Turning Point Therapeutics
$69.35 /

+1.05 (+1.54%)

AZN AstraZeneca
$55.24 /

+0.19 (+0.35%)

TPTX Turning Point Therapeutics
$69.35 /

+1.05 (+1.54%)

05/06/21 Roth Capital
Turning Point 'significantly undervalued' with catalysts ahead, says Roth
04/13/21 Roth Capital
Turning Point combo data show 'expansive pipeline potential,' says Roth Capital
04/06/21 Roth Capital
Turning Point price target raised to $175 from $170 at Roth Capital
03/02/21 Roth Capital
Turning Point has 'many value-driving catalysts' in 2021, says Roth Capital
AZN AstraZeneca
$55.24 /

+0.19 (+0.35%)

05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/12/21
Fly Intel: Top five analyst downgrades
TPTX Turning Point Therapeutics
$69.35 /

+1.05 (+1.54%)

AZN AstraZeneca
$55.24 /

+0.19 (+0.35%)

  • 27
    Oct
  • 19
    May
AZN AstraZeneca
$55.24 /

+0.19 (+0.35%)

TPTX Turning Point Therapeutics
$69.35 /

+1.05 (+1.54%)

AZN AstraZeneca
$55.24 /

+0.19 (+0.35%)

AZN AstraZeneca
$55.24 /

+0.19 (+0.35%)

Recommendations
Turning Point 'significantly undervalued' with catalysts ahead, says Roth » 09:41
05/06/21
05/06
09:41
05/06/21
09:41
TPTX

Turning Point Therapeutics

$70.61 /

-0.08 (-0.11%)

Turning Point…

Turning Point Therapeutics showed "stellar progress" in Q1, including getting its third and fourth investigational new drug clearances, Roth Capital analyst Zegbeh Jallah tells investors in a research note. The analyst says that with the platform validation from Repotrectinib and multiple programs in the clinic, the stock is "significantly undervalued." Turning Point has sufficient cash into 2024 and "multiple catalysts ahead," contends Jallah, who keeps a Buy rating on the shares with a $175 price target.

ShowHide Related Items >><<
TPTX Turning Point Therapeutics
$70.61 /

-0.08 (-0.11%)

TPTX Turning Point Therapeutics
$70.61 /

-0.08 (-0.11%)

04/13/21 Roth Capital
Turning Point combo data show 'expansive pipeline potential,' says Roth Capital
04/06/21 Roth Capital
Turning Point price target raised to $175 from $170 at Roth Capital
03/02/21 Roth Capital
Turning Point has 'many value-driving catalysts' in 2021, says Roth Capital
02/02/21 Canaccord
Turning Point Therapeutics price target raised to $145 from $122 at Canaccord
TPTX Turning Point Therapeutics
$70.61 /

-0.08 (-0.11%)

  • 27
    Oct
  • 19
    May
TPTX Turning Point Therapeutics
$70.61 /

-0.08 (-0.11%)

Over a quarter ago
Recommendations
Turning Point combo data show 'expansive pipeline potential,' says Roth Capital » 10:36
04/13/21
04/13
10:36
04/13/21
10:36
TPTX

Turning Point Therapeutics

$74.66 /

-0.21 (-0.28%)

Roth Capital analyst…

Roth Capital analyst Zegbeh Jallah keeps a Buy rating on Turning Point Therapeutics with a $175 price target after the company presented data from three of its four clinical programs at the recent American Association for Cancer Research meeting. The analyst highlights the MEK and PD-1 combo data, saying it broadens the use-case of Turning Point's tyrosine kinase inhibitors as "indicative of its expansive pipeline potential." Repotrectinib is a potent NTRK/ROS-1 inhibitor with potential for combo efficacy in KRAS mutant cancers, Jallah tells investors in a research note.

ShowHide Related Items >><<
TPTX Turning Point Therapeutics
$74.66 /

-0.21 (-0.28%)

TPTX Turning Point Therapeutics
$74.66 /

-0.21 (-0.28%)

04/06/21 Roth Capital
Turning Point price target raised to $175 from $170 at Roth Capital
03/02/21 Roth Capital
Turning Point has 'many value-driving catalysts' in 2021, says Roth Capital
02/02/21 Canaccord
Turning Point Therapeutics price target raised to $145 from $122 at Canaccord
01/29/21 Roth Capital
Turning Point Therapeutics price target raised to $170 from $140 at Roth Capital
TPTX Turning Point Therapeutics
$74.66 /

-0.21 (-0.28%)

  • 27
    Oct
  • 19
    May
TPTX Turning Point Therapeutics
$74.66 /

-0.21 (-0.28%)

Hot Stocks
Turning Point initiates Phase 1/2 Forge-1 study of TPX-0131 » 09:09
04/12/21
04/12
09:09
04/12/21
09:09
TPTX

Turning Point Therapeutics

$78.82 /

-2.89 (-3.54%)

Turning Point…

Turning Point Therapeutics announced initiation of its Phase 1/2 FORGE-1 study of TPX-0131, a potent inhibitor of the anaplastic lymphoma kinase and multiple resistant mutations of ALK. The investigational new drug application for TPX-0131 is Turning Point's third IND to be cleared by the FDA in less than 2 years, and FORGE-1 is the company's fourth clinical study to initiate during the same period of time. The study was initiated in Australia, with U.S. site activations now planned. ALK alterations are estimated to be responsible for 3% to 5% of non-small cell lung cancer cases annually in the U.S. and EU5 countries. In preclinical studies, TPX-0131 potently inhibits wildtype ALK and is more potent in comparison to approved ALK inhibitors against many clinically observed resistance mutations, including the G1202R solvent front mutation, L1196M gatekeeper mutation, and multiple compound mutations. In addition, TPX-0131 has shown brain tissue penetration after repeat oral dosing. The Phase 1 dose finding portion of the FORGE-1 study will enroll patients with locally advanced or metastatic TKI-pretreated ALK-positive NSCLC. Patients with up to 2 prior ALK TKIs and 1 prior platinum-based chemotherapy will be enrolled. The study endpoints include safety and tolerability, determination of the maximum tolerated dose and/or the recommended Phase 2 dose, and objective response rate by RECIST 1.1.

ShowHide Related Items >><<
TPTX Turning Point Therapeutics
$78.82 /

-2.89 (-3.54%)

TPTX Turning Point Therapeutics
$78.82 /

-2.89 (-3.54%)

04/06/21 Roth Capital
Turning Point price target raised to $175 from $170 at Roth Capital
03/02/21 Roth Capital
Turning Point has 'many value-driving catalysts' in 2021, says Roth Capital
02/02/21 Canaccord
Turning Point Therapeutics price target raised to $145 from $122 at Canaccord
01/29/21 Roth Capital
Turning Point Therapeutics price target raised to $170 from $140 at Roth Capital
TPTX Turning Point Therapeutics
$78.82 /

-2.89 (-3.54%)

  • 27
    Oct
  • 19
    May
TPTX Turning Point Therapeutics
$78.82 /

-2.89 (-3.54%)

Hot Stocks
Turning Point Therapeutics announces new preclinical data for three drugs » 09:04
04/09/21
04/09
09:04
04/09/21
09:04
TPTX

Turning Point Therapeutics

$81.83 /

+1.09 (+1.35%)

Turning Point…

Turning Point Therapeutics announced new preclinical data supporting the ongoing development of three of its drug candidates, repotrectinib, TPX-0022 and TPX-0131. The findings will be presented this weekend at the American Association for Cancer Research annual meeting, which is convening virtually through April 14. For lead drug candidate, repotrectinib, poster presentations will highlight new preclinical combination data with MEK and MEK/Raf inhibitors, as well as repotrectinib's potency against wildtype and mutant TRKA/B/C as compared to approved TRK inhibitors. The preclinical studies found that repotrectinib combinations with approved MEK inhibitor, trametinib, or investigational MEK/Raf inhibitor, VS-6766, were more effective than single-agent treatment in patient-derived KRAS mutant G12D/V lung and G12D/V/R pancreatic cancer models. Based on the findings and additional preclinical support presented previously, Turning Point anticipates the first cohort of its planned Phase 1/2 TRIDENT-2 study will examine the safety, tolerability, pharmacokinetics, and any early signals of efficacy of repotrectinib in combination with trametinib in patients with KRAS mutant G12D advanced solid tumors. For MET/SRC/CSF1R inhibitor TPX-0022, the company will present preclinical data demonstrating potential utility in combination with immune checkpoint inhibitors. In a syngeneic xenograft tumor model, TPX-0022 treatment downregulated immunosuppressive cytokines, increased anti-tumor M1 macrophages, and enriched levels of CD8+ cytotoxic T cells. TPX-0022 had single agent in vivo efficacy and enhanced the efficacy of an anti-PD-1 inhibitor. With the new data, Turning Point is evaluating a potential additional combination study of TPX-0022 and an anti-PD-1 checkpoint inhibitor. In the second half of 2021, the company plans to provide a clinical data update from the Phase 1 dose finding portion of its ongoing SHIELD-1 study and initiate its planned Phase 1b/2 SHIELD-2 clinical study of TPX-0022 in combination with an EGFR targeted therapy. For its ALK-inhibitor, TPX-0131, Turning Point will present preclinical data showing its potential to cross the blood-brain barrier and its potency against wild type ALK and a broad spectrum of acquired ALK resistance mutations, including the G1202R solvent front mutation, L1196M gatekeeper mutation, and the G1202R/L1196M and /L1198F compound mutations. Turning Point plans to initiate a Phase 1/2 study in patients with ALK-positive TKI-pretreated advanced non-small cell lung cancer in the Q2.

ShowHide Related Items >><<
TPTX Turning Point Therapeutics
$81.83 /

+1.09 (+1.35%)

TPTX Turning Point Therapeutics
$81.83 /

+1.09 (+1.35%)

04/06/21 Roth Capital
Turning Point price target raised to $175 from $170 at Roth Capital
03/02/21 Roth Capital
Turning Point has 'many value-driving catalysts' in 2021, says Roth Capital
02/02/21 Canaccord
Turning Point Therapeutics price target raised to $145 from $122 at Canaccord
01/29/21 Roth Capital
Turning Point Therapeutics price target raised to $170 from $140 at Roth Capital
TPTX Turning Point Therapeutics
$81.83 /

+1.09 (+1.35%)

  • 27
    Oct
  • 19
    May
TPTX Turning Point Therapeutics
$81.83 /

+1.09 (+1.35%)

Conference/Events
Turning Point Therapeutics management to meet virtually with Wedbush » 10:55
04/06/21
04/06
10:55
04/06/21
10:55
TPTX

Turning Point Therapeutics

$83.67 /

-6.23 (-6.93%)

Virtual Meeting to be…

Virtual Meeting to be held on April 7 at 11:30 am hosted by Wedbush.

ShowHide Related Items >><<
TPTX Turning Point Therapeutics
$83.67 /

-6.23 (-6.93%)

TPTX Turning Point Therapeutics
$83.67 /

-6.23 (-6.93%)

04/06/21 Roth Capital
Turning Point price target raised to $175 from $170 at Roth Capital
03/02/21 Roth Capital
Turning Point has 'many value-driving catalysts' in 2021, says Roth Capital
02/02/21 Canaccord
Turning Point Therapeutics price target raised to $145 from $122 at Canaccord
01/29/21 Roth Capital
Turning Point Therapeutics price target raised to $170 from $140 at Roth Capital
TPTX Turning Point Therapeutics
$83.67 /

-6.23 (-6.93%)

  • 27
    Oct
  • 19
    May
TPTX Turning Point Therapeutics
$83.67 /

-6.23 (-6.93%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.